Biopolym. Cell. 2020; 36(3):229-241.
http://dx.doi.org/10.7124/bc.000A2F
Bioorganic Chemistry
5-Ene-rhodanine-3-carboxylic acids as potential antimicrobial and antiparasitic agents
1Kryshchyshyn-Dylevych A. P.
  1. Danylo Halytsky Lviv National Medical University
    69, Pekarska Str., Lviv, Ukraine, 79010

Abstract

Aim. Design, synthesis and study of antibacterial, antifungal and trypanocidal activity of a series of novel 2-thioxo-4-thiazolidinone-3-carboxylic acids with different arylidene substituents in C5 position. Methods: organic wet synthesis, analytical and spectral methods, pharmacological screening, SAR analysis. Results. A series of 5-(aminomethylene)-4-oxo-2-thioxothiazolidin-3-ylcarboxylic acids and their analogs IIIa-IIIj were synthesized in the reactions of 5-(ethoxymethylene)-4-oxo-2-thioxothiazolidin-3-ylcarboxylic acids IIa,b or ethyl 5-(ethoxymethylene)-4-oxo-2-thioxothiazolidin-3-ylpropanoate IIc with various amines and ammonium hydrogen carbonate. Five of the synthesized compounds IIIb, IIIf and IIIh-j were tested towards a series of Gram (+) and Gram (–) bacteria and four yeasts strains at a dose of 1mM. In general, [the] tested compounds are promising building scaffolds for the development of antifungal agents as all of them inhibited growth of clinical strain of Candida albicans. Moreover, pyridine containing 3-[5-(aminomethylene)-rhodanine-3-yl]carboxylates showed good trypanocidal activity and low cytotoxicity towards normal fibroblasts. Conclusions. A series of novel 3-[5-(aminomethylene)-4-oxo-2-thioxothiazolidin-3-yl]carboxylic acids derivatives were synthesized. Study of their antibacterial and antifungal action allowed identifying a hit-compound ethyl 3-[5-[(4-(fluoroanilino)methylene]-4-oxo-2-thioxothiazolidin-3-yl]propanoate IIIf, which is active against clinical strains of Staphylococcus lentus and Candida ssp. In general, most of the studied compounds showed good antifungal properties.
Keywords: 2-thioxo-4-thiazolidinone-3-carboxylic acids, rhodanine, synthesis, antitrypanosomal activity, antibacterial activity, antifungal activity, SAR
Full text: (PDF, in English)

References

[1] Kaminskyy D, Kryshchyshyn A, Lesyk R. 5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry. Eur J Med Chem. 2017; 140: 542-94.
[2] Havrylyuk D, Roman O, Lesyk R. Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole/pyrazoline-thiazolidine-based hybrids. Eur J Med Chem. 2016; 113: 145-66.
[3] Tripathi AC, Gupta SJ, Fatima GN, Sonar PK, Verma A, Saraf SK. 4-Thiazolidinones: The advances continue. Eur J Med Chem. 2014; 72: 52-77.
[4] Kryshchyshyn A, Kaminskyy D, Karpenko O, Gzella A, Grellier P, Lesyk R. Thiazolidinone/thiazole based hybrids - New class of antitrypanosomal agents. Eur J Med Chem. 2019; 174: 292-308.
[5] Kryshchyshyn A, Kaminskyy D, Grellier P, Lesyk R. Thiazolidinone-Related Heterocyclic Compounds as Potential Antitrypanosomal Agents. In Azoles - Synthesis, Properties, Applications and Perspectives. IntechOpen, 2020.
[6] da Silva EB, Oliveira e Silva DA, Oliveira AR, da Silva Mendes CH, dos Santos TAR, da Silva AC, de Castro MCA, Ferreira RS, Moreira DRM, Cardoso MV de O, de Simone CA, Pereira VRA, Leite ACL. Desing and syn-thesis of potent anti - Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death. Eur J Med Chem. 2017; 130: 39-50.
[7] Kryshchyshyn-Dylevych AP, Zelisko NI, Grellier P, Lesyk RB. Preliminary evaluation of thiazolidinone- and pyrazoline-related heterocyclic derivatives as potential antimalarial agents. Biopolym Cell. 2020; 36(1): 48-60.
[8] Tomasic T, Masic L. Rhodanine as a Privileged Scaffold in Drug Discovery. Curr Med Chem. 2009; 16(13): 1596-629.
[9] Kaminskyy D, Kryshchyshyn A, Lesyk R. Recent developments with rhodanine as a scaffold for drug discovery. Expert Opin Drug Discov. 2017; 12(12): 1233-52.
[10] Kaminskyy D V., Lesyk RB. Structure-anticancer activity relationships among 4-azolidinone-3-carboxylic acids derivatives. Biopolym Cell. 2010; 26(2): 136-45.
[11] Kryshchyshyn A, Kaminskyy D, Roman O, Kralovics R, Karpenko O, Lesyk R. Synthesis and anti-leukemic activity of pyrrolidinedione-thiazolidinone hybrids. Ukr Biochem J. 2020; 92(2): 108-19.
[12] Kaminskyy D. A Facile Synthesis and Anticancer Activity Evaluation of Spiro[Thiazolidinone-Isatin] Conjugates. Sci Pharm. 2011; 79(4): 763-77.
[13] Lesyk RB, Zimenkovsky BS, Kaminskyy D V., Kryshchyshyn AP, Havryluk DY, Atamanyuk D V., Subtel'na IY, Khyluk D V. Thiazolidinone motif in anticancer drug discovery Experience of DH LNMU medicinal chemistry scientific group. 2011; 27(2): 107-17.
[14] Baell JB, Nissink JWM. Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations. ACS Chem Biol. 2018; 13(1): 36-44.
[15] Mendgen T, Steuer C, Klein CD. Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhoda-nines and Related Heterocycles in Medicinal Chemistry. J Med Chem. 2012; 55(2): 743-53.
[16] Maddila S, Gorle S, Jonnalagadda SB. Drug screening of rhodanine derivatives for antibacterial activity. Expert Opin Drug Discov. 2020; 15(2): 203-29.
[17] Jackson N, Czaplewski L, Piddock LJ V. Discovery and development of new antibacterial drugs: learning from experience? J Antimicrob Chemother. 2018; 73(6): 1452-9.
[18] Sundaram K, Ravi S. Synthesis, antibacterial activity against MRSA, and in vitro cytotoxic activity against HeLa cell lines of novel 3-α-carboxy ethyl-5-benzylidene rhodanine derivatives. Res Chem Intermed. 2015; 41(2): 1011-21.
[19] Brvar M, Perdih A, Hodnik V, Renko M, Anderluh G, Jerala R, Solmajer T. In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B. Bioorg Med Chem. 2012; 20(8): 2572-80.
[20] Tejchman W, Korona-Glowniak I, Malm A, Zylewski M, Suder P. Antibacterial properties of 5-substituted derivatives of rhodanine-3-carboxyalkyl acids. Med Chem Res. 2017; 26(6): 1316-24.
[21] Li W, Zheng C-J, Sun L-P, Song M-X, Wu Y, Li Y-J, Liu Y, Piao H-R. Novel arylhydrazone derivatives bearing a rhodanine moiety: synthesis and evaluation of their antibacterial activities. Arch Pharm Res. 2014; 37(7): 852-61.
[22] Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014; 10: 95-105.
[23] Wilson D, Dimondi V, Johnson S, Jones T, Drew R. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016; 12: 1197-206.
[24] AbdelKhalek A, Ashby CR, Patel BA, Talele TT, Seleem MN. In Vitro Antibacterial Activity of Rhodanine Derivatives against Pathogenic Clinical Isolates. PLoS One. 2016; 11(10): e0164227.
[25] Nagahara M, Ohishi Y, Yajima M, Nogimori K, Kurokawa S, Kajikawa N. Rhodanines useful as a therapeutic agent for diabetic complications. USPat. 4606860A. Appl. no.: 675,580 28.11.1984. Published 19.08.1986.
[26] Wojtyra MN. Synthesis and biological activity of thiazolidine derivatives with pyridine moiety in molecules. Thesis for candidate's degree in pharmaceutical sciences in the speciality 15.00.02. Danylo Halytsky LNMU, Lviv 2017.
[27] EUCAST. c Eur Soc Clin Microbiol Infect Deseases. 2020; (January): 1-21.
[28] Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18(3): 268-81.
[29] Lethu S, Bosc D, Mouray E, Grellier P, Dubois J. New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis. J Enzyme In-hib Med Chem. 2013; 28(1): 163-71.
[30] Pérez-Cruz F, Serra S, Delogu G, Lapier M, Maya JD, Olea-Azar C, Santana L, Uriarte E. Antitrypanosomal and antioxidant properties of 4-hydroxycoumarins derivatives. Bioorganic Med Chem Lett. 2012; 22(17): 5569-73.
[31] Körner H. Über einige Derivate der Dithiocarbamino-essigsäure. Berichte der Dtsch Chem Gesellschaft. 1908; 41(2): 1901-5.
[32] Holota S, Kryshchyshyn A, Derkach H, Trufin Y, Demchuk I, Gzella A, Grellier P, Lesyk R. Synthesis of 5-enamine-4-thiazolidinone derivatives with trypanocidal and anticancer activity. Bioorg Chem. 2019; 86: 126-36.
[33] Bolognesi ML, Cavalli A. Multitarget Drug Discovery and Polypharmacology. ChemMedChem. 2016; 11(12): 1190-2.
[34] Bottegoni G, Favia AD, Recanatini M, Cavalli A. The role of fragment-based and computational methods in polypharmacology. Drug Discov Today. 2012; 17(1-2): 23-34.
[35] Kryshchyshyn A. Fragment-based drug design (FBDD). J Org Pharm Chem. 2017; 15(1 (57)): 28-44.